12/11/2024
Dose Escalation Approved and Dosing Commenced in Second Cohort of GPN Vaccines’ Phase 1 Clinical Trial in Older Adults
Adelaide, Australia, 12 th November 2024 – GPN Vaccines Ltd is pleased to announce that dose escalation has…
News
Read article
17/10/2024GPN Vaccines Welcomes Dr. Bruce Forrest as Chief Scientific Officer
Read articleAdelaide, Australia, 17th October 2024 – GPN Vaccines Ltd is thrilled to announce the appointment of Dr. Bruce…
04/09/2024First Participant Dosed in Phase 1 Clinical Trial of Gamma-PN in Older Adults
Read articleAdelaide, Australia, 5th September 2024 – GPN Vaccines Ltd is pleased to announce that the first participant has…
21/08/2024GPN Vaccines Secures Ethics Approval for a Clinical Trial of its Pneumococcal Vaccine in Older Adults
Read articleAdelaide, Australia, 21st August 2024 GPN Vaccines is pleased to announce it has received ethics approval to commence…
- 05/06/2024
GPN Vaccines Closes $18M Series B1 Round
Read articleAdelaide, Australia, 6th June 2024 – GPN Vaccines is pleased to announce the closing of its oversubscribed Series…
- 07/05/2024
GPN Vaccines Awarded CUREator Funding
Read articleAdelaide, Australia – 7th May 2024 GPN Vaccines Ltd is pleased to announce the successful award of $936,000…
